TDZD-8

TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.


Cat. No.: EX-A109	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	450	In-stock
500mg	650	In-stock
1g	985	In-stock
5g	2880	In-stock
10g	4380	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	GSK-3β Inhibitor I
Synonyms 2	NP 01139
CAS No.	327036-89-5
Purity	>98%
Formula	C10H10N2O2S
Mol Weight	222.264
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Martinez A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 2002 Mar 14;45(6):1292-9. [2]. Xie CL, et al. Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. Sci Rep. 2016 Mar 21;6:23527. [3]. Sun A, et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. Prostate. 2016 Feb;76(2):172-83.
CoA	CoA of TDZD-8

Smiles:	CN1SC(=O)N(CC2=CC=CC=C2)C1=O


		Search